A Study of Tocilizumab in Chinese Participants With Systemic Juvenile Idiopathic Arthritis (sJIA)

NCT03301883 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

62

Enrollment

INDUSTRY

Sponsor class

Conditions

Juvenile Idiopathic Arthritis

Interventions

DRUG: Tocilizumab
DRUG: NSAIDs
DRUG: CSs
DRUG: MTX

Sponsor

Hoffmann-La Roche